Cwm LLC Has $3.49 Million Stock Holdings in Boston Scientific Corporation $BSX

Cwm LLC reduced its position in shares of Boston Scientific Corporation (NYSE:BSX) by 22.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 36,604 shares of the medical equipment provider’s stock after selling 10,695 shares during the period. Cwm LLC’s holdings in Boston Scientific were worth $3,490,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Parnassus Investments LLC boosted its position in Boston Scientific by 42,978.9% during the 3rd quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock worth $672,128,000 after buying an additional 6,868,459 shares during the period. Egerton Capital UK LLP increased its position in Boston Scientific by 223.7% in the 3rd quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock valued at $518,660,000 after acquiring an additional 3,671,548 shares during the period. Jennison Associates LLC raised its stake in shares of Boston Scientific by 133.5% during the third quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider’s stock valued at $482,170,000 after acquiring an additional 2,823,744 shares during the last quarter. Marshall Wace LLP raised its stake in shares of Boston Scientific by 30.7% during the third quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider’s stock valued at $956,680,000 after acquiring an additional 2,301,383 shares during the last quarter. Finally, Credit Agricole S A acquired a new position in shares of Boston Scientific during the third quarter worth $204,812,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Activity

In related news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the sale, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This represents a 10.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.34% of the stock is owned by corporate insiders.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $64.95 on Thursday. Boston Scientific Corporation has a twelve month low of $59.38 and a twelve month high of $109.50. The firm has a fifty day simple moving average of $68.87 and a 200 day simple moving average of $86.16. The company has a market capitalization of $96.53 billion, a PE ratio of 33.48, a P/E/G ratio of 0.92 and a beta of 0.78. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The business had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. During the same quarter in the prior year, the firm posted $0.75 earnings per share. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, sell-side analysts forecast that Boston Scientific Corporation will post 3.45 EPS for the current year.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q1 results beat and solid top-line growth — Q1 revenue of ~$5.20B and adjusted EPS $0.80 topped estimates and showed 11.6% sales growth, which underpins the bullish reaction. Boston Scientific announces results for first quarter 2026
• Positive Sentiment: Analysts largely kept Buy ratings and reaffirmed long‑term upside (Jefferies, Barclays kept constructive views despite trimming PTs), supporting investor confidence. Balancing Near-Term Guidance Cuts With Long-Term Growth Drivers
• Neutral Sentiment: Several firms trimmed price targets (e.g., Barclays, Jefferies, Stifel lowered PTs to ~$85–$100) — still implying meaningful upside from current levels, but reflecting a nearer‑term reset. Benzinga coverage of analyst updates
• Neutral Sentiment: Unusually large options activity and heavy trading volume signaled speculative and institutional positioning into the print, adding to intraday momentum. Why Is Boston Scientific Stock Soaring Wednesday?
• Negative Sentiment: Management cut FY‑2026 and Q2 guidance (EPS and revenue ranges came in below consensus), which is a clear headwind for near‑term expectations. Boston Scientific cuts 2026 profit forecast, trims revenue growth view
• Negative Sentiment: Multiple class‑action lawsuits and investor alerts were filed/announced, creating legal overhang and potential costs or distraction for management. BSX Investor Alert: Securities Fraud Lawsuit

Analyst Ratings Changes

BSX has been the topic of several analyst reports. Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. Truist Financial lowered their target price on Boston Scientific from $92.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, April 15th. BTIG Research reiterated a “buy” rating on shares of Boston Scientific in a research report on Wednesday. National Bank Financial set a $115.00 price target on Boston Scientific in a research note on Monday, February 2nd. Finally, Argus upgraded Boston Scientific to a “strong-buy” rating in a research report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Boston Scientific currently has a consensus rating of “Moderate Buy” and an average price target of $101.04.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.